Get the Stockscreener App
0.2263
9.04%
-0.0225
After Hours:
.23
0.0037
+1.63%
In 8 Bio Inc stock is traded at $0.2263, with a volume of 1.82M.
It is down -9.04% in the last 24 hours and down -29.96% over the past month.
IN8bio Inc is a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of gamma-delta T cell product candidates for solid and liquid tumors, by employing allogeneic, autologous, and genetically modified gamma-delta T cells. Its product candidates include INB-400, for the treatment of newly diagnosed glioblastoma, or GBM, INB-100 for the treatment of patients with high-risk leukemias undergoing hematopoietic stem cell transplantation, and other product candidates such as INB-200, INB-300, and INB-500.
See More
Previous Close:
$0.2488
Open:
$0.2525
24h Volume:
1.82M
Relative Volume:
0.37
Market Cap:
$16.40M
Revenue:
-
Net Income/Loss:
$-31.88M
P/E Ratio:
-0.3017
EPS:
-0.75
Net Cash Flow:
$-25.20M
1W Performance:
-12.52%
1M Performance:
-29.96%
6M Performance:
-28.50%
1Y Performance:
-81.90%
1-Day Range:
$0.2173
$0.2525
1-Week Range:
$0.2173
$0.2621
52-Week Range:
$0.217
$1.74
In 8 Bio Inc Stock (INAB) Company Profile
Name
In 8 Bio Inc
Sector
Industry
Phone
(646) 600-6438
Address
EMPIRE STATE BUILDING, NEW YORK
Compare INAB with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
INAB
In 8 Bio Inc
|
0.2263 | 16.40M | 0 | -31.88M | -25.20M | -0.75 |
|
VRTX
Vertex Pharmaceuticals Inc
|
502.92 | 129.14B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
680.61 | 74.41B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
581.21 | 35.31B | 2.19B | 833.04M | -1.28B | 12.71 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
241.75 | 31.30B | 2.25B | -278.16M | -42.59M | -2.17 |
|
ONC
Beigene Ltd Adr
|
254.57 | 27.35B | 3.32B | -860.46M | -1.04B | -8.32 |
In 8 Bio Inc Stock (INAB) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Mar-18-24 | Initiated | Laidlaw | Buy |
| Aug-30-22 | Initiated | H.C. Wainwright | Buy |
In 8 Bio Inc Stock (INAB) Latest News
Shareholder Alert: The Ademi Firm investigates whether 2seventy bio, Inc. is obtaining a Fair Price for its Public Shareholders - Joplin Globe
Why Paymentus Holdings Shares Are Trading Higher By Over 8%; Here Are 20 Stocks Moving Premarket - Benzinga
2seventy bio Enters into Definitive Agreement to be Acquired by Bristol Myers Squibb - Business Wire
Nuvation Bio Inc. (NUVB): Among the Best NYSE Penny Stocks to Buy According to Analysts - Yahoo Finance
Gossamer Bio Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) - Business Wire
Q32 Bio Inc expected to post a loss of $1.51 a shareEarnings Preview - TradingView
Nuvation Bio Inc reports results for the quarter ended December 31Earnings Summary - TradingView
Passage Bio Inc reports results for the quarter ended December 31Earnings Summary - TradingView
Palisade Bio Participates in Virtual Investor “What This Means” Segment - GlobeNewswire
Entera Bio Ltd expected to post a loss of 8 cents a shareEarnings Preview - TradingView
Tevogen Bio to Receive $8 Million of Non-Dilutive Grant Funding, Reiterates Efficient Operations - Yahoo Finance
Canadian North Resources Inc. Expands Metallurgical Programs Applying Low-carbon Footprint Bioleaching Technology on Ferguson Lake Ni-Cu-Co PGE project - Yahoo Canada Finance
Pre-market Movers: BTAI, VRPX, DCGO, NBY... - RTTNews
Global Nucleic Acid Amplification Testing Market to Grow Rapidly at an ~8% CAGR by 2032 | DelveInsight - GlobeNewswire
Genetic Medicine Pioneer Passage Bio Sets March Investor Conference Schedule - StockTitan
Title: bluebird bio Announces Positive Phase 1/2 Clinical Trial Data for Gene Therapy - Defense World
Tevogen Bio’s First Trading Year Efficiency: 600% Higher Market Cap Per Team Member, 79% Insider-Owned - Yahoo Finance
What's Going On With Gene Therapy Company Bluebird Bio Stock Today? - Benzinga
Palisade Bio, Inc. Announces Receipt of Cash Proceeds from - GlobeNewswire
Annovis to Host Patients' Live Forum on February 27, 2025 - Quantisnow
Palisade Bio, Inc. Participates in the Virtual Investor “Top 5 for ‘25” On-Demand Conference - The Globe and Mail
IN8bio Presents Positive Phase 1 Data at TCT 2025, Highlighting Durability of Remissions in High-Risk AML - GlobeNewswire Inc.
KALA BIO Announces Chief Executive Officer Transition - GlobeNewswire
Plug Power (NASDAQ:PLUG) Enters Into Standby Equity Purchase Agreement with YA II PN, LTD - Defense World
INmune Bio Inc. Discloses New Investor and Webinar PresentationsOn February 10, 2025, INmune Bio Inc. (NASDAQ: INMB) submitted an 8-K form to the Securities and Exchange Commission, revealing that the company had developed an Investor Presentati - Defense World
Third Harmonic Bio, Inc. Announces Restructuring Plan - TipRanks
Mustang Bio Closes $8 Million Public Offering - citybiz
Palisade Bio Presents Positive Preclinical Data of PALI-2108 for the Treatment of Ulcerative Colitis - GlobeNewswire
Mustang Bio Announces Closing of $8 Million Public Offering - The Manila Times
Mustang Bio, Inc. Completes Public Offering, Raising Approximately $8 Million for Cancer Cell Therapy Development - Nasdaq
INmune Bio Announces Plan to Submit FDA Biologics License Application (BLA) Seeking Approval of CORDStrom for Treatment of Recessive Dystrophic Epidermolysis Bullosa (RDEB) - The Manila Times
Bluebird bio Inc (NASDAQ: BLUE) Now Carries A 12-Month Price Target Of $25. - Marketing Sentinel
Annovis to Present at Oppenheimer's 35th Annual Healthcare Life Sciences Conference - Quantisnow
Mustang Bio Announces Pricing of $8 Million Public Offering - GlobeNewswire
Capital Raise Alert: Mustang Bio Secures Fresh $8M Funding Through Strategic Share & Warrant Offering - StockTitan
Annovis Announces First Patients Entered into Pivotal Phase 3 Study of Buntanetap for Early Alzheimer's Disease - Quantisnow
Annovis Bio, Inc. Announces Closing of $21 Million Public Offering - Quantisnow
Why INmune Bio Inc (INMB) Is Skyrocketing So Far In 2025 - Insider Monkey
Annovis Bio, Inc. Announces Pricing of $21 Million Public Offering - Quantisnow
Passage Bio shares transition to Nasdaq Capital Market - Investing.com
Annovis Bio, Inc. Announces Proposed Public Offering - Quantisnow
Adicet Bio Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4) - Business Wire
Palisade Bio Selected for Poster Presentation at the 2025 Crohn’s & Colitis Congress - Yahoo Finance
SAB BIO Announces Positive Topline Phase 1 Clinical Results - GlobeNewswire
Palisade Bio to Present at LIVE! with Webull Corporate Connect: Healthcare Investment Webinar - GlobeNewswire
Breakeven On The Horizon For Belite Bio, Inc (NASDAQ:BLTE) - Yahoo Finance UK
Cabaletta Bio Discloses Unaudited Cash and Cash Equivalents of $164 Million as of December 31, 2024 - Defense World
Palisade Bio Completes All Five SAD Cohorts and Advances to - GlobeNewswire
Vyant Bio (OTCMKTS:VYNT) Shares Up 7.8% – Time to Buy? - Defense World
Mustang Bio Announces Reverse Stock Split - GlobeNewswire
Passage Bio (NASDAQ:PASG) Announces Restructuring Plan and Financial Update - Defense World
In 8 Bio Inc Stock (INAB) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.39%
0.55%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):